<DOC>
	<DOCNO>NCT00212888</DOCNO>
	<brief_summary>The purpose study determine vaccination structure treatment interruption ( STI ) associate improvement immune function , result delay reduce rebound amount HIV virus blood .</brief_summary>
	<brief_title>Combination Vaccination Before HIV Treatment Interruption</brief_title>
	<detailed_description>Volunteers randomly assign receive vaccine match placebo interrupt antiretroviral therapy week 24 . Dosage : Remune ( TM ) 1 ml i.m . * week 0 , 12 , 20 ; ALVAC 1 ml i.m . * week 8,12 , 16 , 20 . * i.m . : injected muscle</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Documented HIV infection ( serology ) HIV RNA level 50 copies/ml least two year Receiving least 2 antiretroviral agent include least 1 protease inhibitor 1 nonnucleoside reverse transcriptase inhibitor time screen Have CD4 count 500 cells/ul Have CD4/CD8 ratio 0.5 Have never CD4 count 250 No previous AIDSdefining opportunistic infection No previous cancer chemotherapy system immunosuppressive therapy ( exclude brief course [ &lt; = 1 month ] prednisone equivalent ) Able provide inform consent Hepatitis B surface antigen positive Hepatitis C antibody positive AST , ALT , ALP , creatinine , urea three time normal upper limit Blood abnormality ( hemoglobin low 100 , white blood cell count [ WBC ] low 1500 platelet low 100 ) Allergies component Remuneâ„¢ ALVAC Contraindications vaccine component Pregnancy breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>HIV</keyword>
	<keyword>Vaccination</keyword>
</DOC>